Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Clinical usefulness of bone turnover marker concentrations in osteoporosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Evaluation of algorithm development approaches: Development of biomarker panels for early detection of colorectal lesions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical proteomics: Insights from IGF-I

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Validation of image cytometry for sperm concentration measurement: Comparison with manual counting of 4010 human semen samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Isotope-dilution TurboFlow-LC-MS/MS method for simultaneous quantification of ten steroid metabolites in serum

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • H A Morris
  • R Eastell
  • N R Jorgensen
  • E Cavalier
  • S Vasikaran
  • S A P Chubb
  • J A Kanis
  • C Cooper
  • K Makris
  • IFCC-IOF Working Group for Standardisation of Bone Marker Assays (WG-BMA)
Vis graf over relationer

Current evidence continues to support the potential for bone turnover markers (BTM) to provide clinically useful information particularly for monitoring the efficacy of osteoporosis treatment. Many of the limitations identified earlier remain, principally in regard to the relationship between BTM and incident fractures. Important data are now available on reference interval values for CTX and PINP across a range of geographic regions and for individual clinical assays. An apparent lack of comparability between current clinical assays for CTX has become evident indicating the possible limitations of combining such data for meta-analyses. Harmonization of units for reporting serum/plasma CTX (ng/L) and PINP (μg/L) is recommended. The development of international collaborations continues with an important initiative to combine BTM results from clinical trials in osteoporosis in a meta-analysis and an assay harmonization program are likely to be beneficial. It is possible that knowledge derived from clinical studies can further enhance fracture risk estimation tools with inclusion of BTM together with other independent risk factors. Further data of the relationships between the clinical assays for CTX and PINP as well as physiological and pre-analytical factors contributing to variability in BTM concentrations are required.

TidsskriftClinica chimica acta; international journal of clinical chemistry
Sider (fra-til)34-41
Antal sider8
StatusUdgivet - apr. 2017

ID: 52120881